DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids.
DNA Script is transforming how molecular biology translates to human health, personalized medicine and synthetic biology.
DNA Script was founded in 2014 by Thomas Ybert and Sylvain Gariel. The company is headquartered in France, with an office in South San Francisco, California.
DNA Script has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System.
The SYNTAX Platform provides in-house DNA printing – without using toxic organic chemicals or extended delivery wait times from third-party DNA service providers – for labs of all sizes.
DNA Script is backed by Coatue Management, Catalio Capital Management, Fidelity Management and Research, T. Rowe Price Associates, Baillie Gifford, Casdin Capital, LSP, Illumina Ventures, Bpifrance, and others. The company completed its Series C round with $200M on Jan 04, 2022. This brings DNA Script's total funding to $312.6M to date.